Hong Kong / HKEX Continues Biotech Momentum in Q3 2021
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
Hong Kong / HKEX Biotech IPOs in the First Half of 2021
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
APAC / HKEX SVP Reflects on Two Years of Pre-Revenue Biotech IPO Listings in Hong Kong
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
APAC / Hong Kong Biotech IPOs since Listing Reform in April 2018
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
Funding / Chinese Biotechs Flock to IPO in Hong Kong
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
Pharma Faces / Hong Kong's Biotech Pioneer
Dr Joseph Tam is indisputably one of the pioneers of Hong Kong’s biotech industry, having returned to Hong Kong in 1973 following an illustrious career in the US to bring…
Pharma CEO Pair Become China’s Richest Couple
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Hansoh IPO Raises $1 Billion on Hong Kong Exchange
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
Bio 2019 / Hong Kong Biotech IPOs Soaring in Line with China Pharma Market
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
Hong Kong Now the World’s Second Largest Funding Hub for Biotech
Hong Kong is now the world’s second largest funding hub for biotech according to Hong Kong Chief Executive Carrie Lam. During her speech at the 2nd HKEx Biotech Summit on…
New Report on Hong Kong Pharma Out Now!
Energetically touting itself as “Asia’s World City” as well as a connector between East and West with its inextricable links to both mainland China and the international community, Hong Kong…